Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

The hormone insulin plays a central role in the metabolism of many living organisms. When food is plentiful, insulin promotes ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

impaired incretin effect, and hepatic IR. Interestingly, these subtypes didn’t always line up with standard measures like HbA1c, underscoring the complexity of glucose regulation. By applying machine ...

The advent of agriculture 12,000 years ago increased the availability of affordable, energy-dense, palatable food, resulting in a substantial effect on the evolutionary physiology of hunger that ...